|
|
 |
|
|
|
|
20. J. N. Gibbs. FDA proposes new drug and biologic reporting requirements. Regulatory Affairs Professionals Society Newsletter. January 1995, p. 6. |
|
|
|
|
|
|
|
|
21. Did liability block AIDS trial? Science 257: 316, 1992. |
|
|
|
|
|
|
|
|
22. 59 Fed. Reg. 39406 (July 22, 1993). |
|
|
|
|
|
|
|
|
23. U.S. FDA alters rules on women in clinical trials. SCRIP 1845: 15, August 10, 1993. |
|
|
|
|
|
|
|
|
24. Specific Requirements on Content and Format of Labeling for Human Prescription Drugs; Revision of Pediatric Use Subsection in the Labeling, 21 CFR Part 201. Docket No. 92N-0165. |
|
|
|
|
|
|
|
|
25. I. Green, M. M. Rumore, G. Torre, and L. Hyman. Drug clinical trials: Do women have equal access? Regulatory Affairs 7: 1, 1995. |
|
|
|
|
|
|
|
|
26. Havner v Merrell Dow Pharmaceuticals Inc. 88-3915-F (Dist. Ct., Nueces Co., Texas), March 17, 1994. |
|
|
|
|
|
|
|
|
27. $19.2 million verdict against Marion Merrell. National Law J. p. B2, July 4, 1994. |
|
|
|
|
|
|
|
|
28. Racketeer Influenced and Corrupt Organization Act. P.L. 91452, Sec. 1, 84 Stat. 22 (1970). |
|
|
|
|
|
|
|
|
29. Upjohn v Oswald, 1992U-111 (High Ct.) England. |
|
|
|
|
|
|
|
|
30. DHHS Federal Tort Claim 93-M-186. |
|
|
|
|
|
|
|
|
31. A. Blum, HalcionR stirs litigation storm. National Law J. p. A1,A23, April 11, 1994. |
|
|
|
|
|
|
|
|
32. Strain of Norplant's High Up-front Costs Has Subsided. U.S. General Accounting Office, HEHS-95-7, October 1994. |
|
|
|
|
|
|
|
|
33. B. Bienz-Tadmor, Pheak Son Sea, and N. Bryant. Research and development, manufacturing, and marketing of biopharmaceuticals: an international comparison. Drug Info. J. 29: 523, 1995. |
|
|
|
|
|
|
|
|
34. J. S. Benson and J. W. Boretos. Biomaterials and the future of medical devices. Medical Device & Diagnostic Industry p. 3237, April 1995. |
|
|
|
|
|
|
|
|
35. J. Wechsler. Getting to the heart of FDA's problems. Pharm. Tech. p. 1420, May 1995. |
|
|
|
|
|
|
|
|
36. J. Wechsler. Getting to first base. Appl. Clin. Trials 3: 12, 1994. |
|
|
|
|
|
|
|
|
37. PhRMA Data. 1995. |
|
|
|
|
|
|
|
|
38. W. W. George. Reinventing the environment for innovation. Medical Device & Diagnostic Industry p. 2432, April 1995. |
|
|
|
|
|
|
|
|
39. M. M. Rumore. Issues on vaccines. Amer. Pharm. 32: 7, 1992. |
|
|
|
|
|
|
|
|
40. Childhood Vaccine Injury Act. P.L. 99660 (1986). |
|
|
|
|
|
|
|
|
41. R. P. Charron. An AIDS vaccine: It may take an Act of Congress. J. NIH Research 6: 84, 1994. |
|
|
|
|
|
|
|
|
42. Farnes v E.R. Squibb & Sons, 92-10250-CA-01 (Cir. Ct., Monroe Co., FL.). |
|
|
|
|
|
|
|
|
43. M. M. Rumore and S. Strauss. Pharmacoepidemiology: regulatory role of the pharmacist. New York State J. Pharm. 11: 42, 1991. |
|
|
|
|
|
|
|
|
44. H. Berkman. Showdown in Senate on Tort Reform. The National Law J. p. A1, A26, May 1, 1995. |
|
|
|
|
|
|
|
|
45. A. Blum. Tort Reform: Camel's Nose into State Law. The National Law J. p. A1, A22, March 20, 1995. |
|
|
|
|
|
|
|
|
46. D. Barker. The effects of tort reform on medical malpractice insurance markets: an empirical analysis. J. Health Politics, Policy and Law 17: 143, 1992. |
|
|
|
|
|
|
|
|
47. W. Griffen. Reforming medical device liability. Medical Device & Diagnostic Industry, p. 110, May 1994. |
|
|
|
|
|